



Sheet 1 of 1

TECH CENTER
MAY 18 2003
JELV

P. 1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01492K

SERIAL NO.:

10/056,680

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

T. Kosoglou, et al.

FILING DATE:

01/25/2002

GROUP:

1743

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SA	AA	Exhibit A: SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary
	AB	Exhibit B: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AC	Exhibit C: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AD	Exhibit D: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AE	Exhibit E: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AF	Exhibit F: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AG	Exhibit G: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AH	Exhibit H: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AI	Exhibit 1: Master Sheet for the SCH 58235 and Lovastatin Research Study, Schering-Plough Research Institute (Protocol No. C906-411), page 1576-1585
	AJ	Exhibit 2: Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, Peninsular Testing Corporation, page 106-112
	AK	Exhibit 3: Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," Schering-Plough Research Institute (Protocol No. C98-010), page 1558-1566
	AL	Exhibit 4: Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, Peninsular Testing Corporation, page 124-130
GH	AM	Exhibit 5: Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," Schering-Plough Research Institute, page 1-8

EXAMINER

DATE CONSIDERED

1/22/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GROUP 1700
MAY 08 2003
RECEIVEDGROUP 1700
MAY 08 2003
RECEIVED

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

SERIAL NO.:

CV01492K

10/056,680

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

T. Kosogl u, et al.

FILING DATE:

01/25/2002

GROUP

1713

RECEIVED
JUN 12 2003
TC 1700

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
SH	AL WO 95/35277	12/28/95	PCT			
	AM EP 1 036 563 A1	09/20/00	EP			
	AN WO 01/96347 A1	12/20/01	PCT			
	AO WO 02/26729 A2	04/04/02	PCT			
	AP WO 02/50027 A1	06/27/02	PCT			
	AQ WO 02/50060 A	06/27/02	PCT			
	AR WO 02/50068 A1	06/27/02	PCT			
SH	AS WO 02/064094 A2	08/22/02	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SH	AT	Kosoglou, et al., "Coadministration of Ezetimibe and Fenofibrate Leads To Favorable Effects On Apo CIII and LDL Subfractions" <i>Atherosclerosis</i> 2:89 (2001)
SH	AU	Davis, et al., "The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs" <i>Metabolism</i> 50(10):1234-41(2001)
SH	AV	
	AW	
	AX	
	AY	
	AZ	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01492K	APPLICATION NO.: 10/056,680
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: T. Kosoglou et al.	
		FILING DATE: 01/25/2002	GROUP: 1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SH	AA	6,030,990	02/29/00	Maeda et al.			
	AB	6,166,049	12/26/00	Smith et al.			
SH	AC	2003/0153541	08/14/03	Dudley et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
SH	AD	WO 01/14351	03/01/01	PCT				
	AE	WO 01/34148	05/17/01	PCT				
	AF	WO 01/60807	08/23/01	PCT				
	AG	WO 02/064094	08/22/02	PCT				
	AH	WO 02/08188	01/31/02	PCT				
	AI	WO 02/26729	04/04/02	PCT				
	AJ	WO 03/039542	05/15/03	PCT				
	AJ	WO 03/074101	09/12/03	PCT				
SH	AL	WO 03/088962	10/30/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


SH	AM	Sorbera et al., Netoglitzzone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139
	AN	Michel Farnier, Nouvelles approches medicamenteuses dans le traitement des dyslipidemies, <i>MT Endocrinologie</i> , 2002, 4:252-259
SH	AO	Berger et al., Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology & Therapeutics</i> , 2002, 4:163-174

EXAMINER <i>Valup...</i>	DATE CONSIDERED <i>1/22/04</i>
-----------------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01492K		SERIAL NO.: 10/056,680	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Teddy Kosoglou, et al.			
				FILING DATE: January 25, 2002		GROUP: 1617	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SM	AA	5,021,461	06/04/91	Robinson et al.			
SM	AB	4,687,777	08/18/87	Meguro et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
SM	AC	WO 97/28149	08/07/97	PCT			
	AD	WO 99/22728	05/14/99	PCT			
	AE	WO 01/96347	12/20/01	PCT			
	AF	WO 02/26729	04/04/02	PCT			
	AG	WO 02/064094	08/22/02	PCT			
	AH	WO 95/35277	12/28/95	PCT			
	AI	WO 02/50027	06/27/02	PCT			
	AJ	WO 02/50060	06/27/02	PCT			
	AK	WO 02/50068	06/27/02	PCT			
	AL	WO 99/08501	02/25/99	PCT			
	AM	WO 94/26738	11/24/94	PCT			
	AN	EP 1 036 563 A1	09/20/00	EPO			
	AO	EP 0 753 298 A1	01/15/97	EPO			
	AP	FR 1103113	10/31/55	FRANCE			X (abs.)
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
SM	AQ	Stuart B. Rosenblum et al., Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, <i>J. Med. Chem.</i> 41:973-980 (1998)					
	AR	Gilbert R. Thompson et al., Novel lipid-regulating drugs, <i>Exp. Opin. Invest. Drugs</i> 9(11):2619-2628 (2000)					
	AS	T. Kosoglou et al., Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects on Apo CIII and LDL Subfractions, <i>Atherosclerosis</i> 2:89 (2001)					
	AT	Harry R. Davis et al., The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs, <i>Metabolism</i> 50 (10):1234-1241 (2001)					
	AU	Study Showed Ezetimibe Significantly Reduced Levels of LDL Cholesterol or "Bad" Cholesterol in Patients, Schering-Plough Press Release					
	AV	T. Kosoglou et al., Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe, <i>Atherosclerosis</i> (2):38 (2001)					
	AW	Remington's Pharmaceutical Sciences, 18 th ed. 1990 p. 1319, 1633-1647					
	AX	Baker S G et al., Treatment of homozygous familial hypercholesterolaemia with probucol, <i>South African Medical Journal</i> (1982)					
	AY	R. Milanese et al., Xantomî E Ipercolesterolemia: Prevalenza, Diagnosi e Terapia, <i>Chron. Derm.</i> 455-61 (1990)					
	EXAMINER <i>Parley H</i>				DATE CONSIDERED 1/22/04		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



GROUP 1700

APR 22 2003

RECEIVED



RECEIVED

APR 25 2003

Sheet 1 of 9

TECH CENTER 1000/2900

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01492K

10/056,680

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

T. Kosoglou et al.

FILING DATE:

January 25, 2002

GROUP:

1743

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SM	FQ	US2003/0013729	01/16/03	Iqbal, et al.	514	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
SM	FR	WO 96/19450	06/27/96	PCT	C07D	205/08		
	FS	WO 97/21676	06/19/97	PCT	C07D	205/09		
	FT	WO 97/41098	11/06/97	PCT	C07D	205/09		
	FU	WO 00/23415	04/27/00	PCT	C07C	69/734		
	FV	WO 00/23416	04/27/00	PCT	C07C	69/734		
	FW	WO 00/23425	04/27/00	PCT	C07D	209/80		
	FX	WO 00/23445	04/27/00	PCT	C07D	471/12		
	FY	WO 00/23451	04/27/00	PCT	C07D	487/14		
	FZ	WO 00/28981	05/25/00	PCT	A61K	31/00		
	GA	WO 00/31548	06/02/00	PCT	G01N	33/68		
	GB	WO 00/32189	06/08/00	PCT	A61K	31/415		
	GC	WO 00/34240	06/15/00	PCT	C07D	205/08		
	GD	WO 00/37057	06/29/00	PCT	A61K	9/48		
	GE	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)	
	GF	WO 00/38721	07/06/00	PCT	A61K	45/06		
	GG	WO 00/38722	07/06/00	PCT	A61K	45/06		
	GH	WO 00/38723	07/06/00	PCT	A61K	45/06		
	GI	WO 00/38724	07/06/00	PCT	A61K	45/06		
	GJ	WO 00/38725	07/06/00	PCT	A61K	45/06		
	GK	WO 00/38726	07/06/00	PCT	A61K	45/06		
	GL	WO 00/38727	07/06/00	PCT	A61K	45/06		
	GM	WO 00/38728	07/06/00	PCT	A61K	45/06		
	GN	WO 00/38729	07/06/00	PCT	A61K	45/06		
	GO	WO 00/40247	07/13/00	PCT	C07D	265/26		
	GP	WO 00/45817	08/10/00	PCT	A61K	31/505		
	GQ	WO 00/50392	08/31/00	PCT	C07C	323/52	X(abs.)	
	GR	WO 00/53149	09/14/00	PCT	A61K			
	GS	WO 00/53173	09/14/00	PCT	A61K	31/22		
	GT	WO 00/53563	09/14/00	PCT	C07C	59/92	X(abs.)	
	GU	WO 00/56403	09/28/00	PCT	A61P	9/10		
	GV	WO 00/57859	10/05/00	PCT	A61K	9/48		
	GW	WO 00/57918	10/05/00	PCT	A61K	47/44		
	GX	WO 00/60107	10/12/00	PCT	C12P	17/10		
	GY	WO 00/63153	10/26/00	PCT	C07C	69/734		
	GZ	WO 00/63161	10/26/00	PCT	C07C	237/30		
	HA	WO 00/63190	10/26/00	PCT	C07D	265/38		
	HB	WO 00/63196	10/26/00	PCT	C07D	277/04		
	HC	WO 00/63209	10/26/00	PCT	C07D	471/04		
SM	HD	WO 00/63703	10/26/00	PCT	G01N	33/92		

Signature 1/22/04



GROUP 1700

APR 22 2003

Sheet

2

RECEIVED

FORM PTO-1472 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

ATTY. DOCKET NO.:
CV01492K

APR 22 2003
10/056,680

APPLICANT:
T. Kosoglou et al.

TECH CENTER 1600/2900

FILING DATE:
January 25, 2002

GROUP:
1743

(Use several sheets if necessary)

51	HE	WO 00/69412	11/23/00	PCT	A61K	9/127		
	HF	WO 00/69445	11/23/00	PCT	A61K	31/785		
	HG	WO 00/72825	12/7/00	PCT	A61K	9/14		
	HH	WO 00/72829	12/07/00	PCT	A61K	9/48		
	HI	WO 00/75103	12/14/00	PCT	C07C	235/60	X(abs.)	
	HJ	WO 00/76482	12/21/00	PCT	A61K	9/48		
	HK	WO 00/76488	12/21/00	PCT	A61K	31/00		
	HL	WO 00/78312	12/28/00	PCT	A61K	31/421		
	HM	WO 00/78313	12/28/00	PCT	A61K	31/422		
	HN	WO 01/00579	01/04/01	PCT	C07D	213/65		
	HO	WO 01/00603	01/04/01	PCT	C07D	277/24		
	HP	WO 01/08686	02/08/01	PCT	A61K	31/495		
	HQ	WO 01/12176	02/22/01	PCT	A61K	31/16		
	HR	WO 01/12187	02/22/01	PCT	A61K	31/404		
	HS	WO 01/12612	02/22/01	PCT	C07D	257/04		
	HT	WO 01/14349	03/01/01	PCT	C07D	277/34	X(abs.)	
	HU	WO 01/14350	03/01/01	PCT	C07D	277/34	X(abs.)	
	HV	WO 01/14351	03/01/01	PCT	C07D	277/34	X(abs.)	
	HW	WO 01/15744	03/08/01	PCT	A61K	49/00		
	HX	WO 01/16120	03/08/01	PCT	C07D	263/32		
	HY	WO 01/17994	03/15/01	PCT	C07D	413/12		
	HZ	WO 01/18210	03/15/01	PCT	C12N	15/12		
	IA	WO 01/21181	03/29/01	PCT	A61K	31/675	X(abs.)	
	IB	WO 01/21259	03/29/01	PCT	A61P			
	IC	WO 01/21578	03/29/01	PCT	C07C	235/60	X(abs.)	
	ID	WO 01/21647	03/29/01	PCT	C07K	14/00		
	IE	WO 01/22962	04/05/01	PCT	A61K	31/435		
	IF	WO 01/25225	04/12/01	PCT	C07D	317/18		
	IG	WO 01/25226	04/12/01	PCT	C07D	327/04		
	IH	WO 01/30343	05/03/01	PCT	A61K	31/40		
	II	WO 01/32161	05/10/01	PCT	A61K	31/00		
	IJ	WO 01/35970	05/25/01	PCT	A61K	35/76		
	IK	WO 01/40192	06/07/01	PCT	C07D	217/26	X(abs.)	
	IL	WO 01/45676	06/28/01	PCT	A61K	9/24		
	IM	WO 01/49267	07/12/01	PCT	A61K	9/14		
	IN	WO 01/64221	09/07/01	PCT	A61K	31/52		
	IO	WO 01/76632	10/18/01	PCT	A61K	45/06		
	IP	WO 02/50090	06/27/02	PCT	C07H	15/26		
	IQ	WO 02/058696	08/01/02	PCT	A61K	31/397		
	IR	WO 02/058731	08/01/02	PCT	A61K	45/06		
	IS	WO 02/058732	08/01/02	PCT	A61K	45/06		
	IT	WO 02/058733	08/01/02	PCT	A61K	45/06		
	IU	WO 02/058734	08/01/02	PCT	A61K	45/06		
	IV	WO 02/058685	08/01/02	PCT	A61K	31/00		
	IW	WO 02/064130	08/22/02	PCT	A61K	31/195		
	IX	WO 02/064549	08/22/02	PCT	C07C	275/34		
52	IY	WO 02/064664	08/22/02	PCT	C08G	77/02		

V. K. Kosoglou 1/22/04



GROUP 1700

APR 22 2003

RECEIVED

Sheet

3

RECEIVED

APR 25 2003

TECH CENTER 1600/2900

FORM PTO-1449				U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01492K		10/056,680	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						APPLICANT: T. Kosoglou et al.			
(Use several sheets if necessary)						FILING DATE: January 25, 2002		GROUP: 1743	
321	IZ	WO 02/072104	09/19/02	PCT		A61K	31/54		
	JA	WO 02/081454	10/17/02	PCT		C07D	239/36		
	JB	WO 02/26729	04/04/02	PCT		C07D	311/66		
	JC	WO 02/064094	08/22/02	PCT		A61K			
	JD	WO 03/018024	03/06/03	PCT		A61K	31/55		
321	JE	WO 03/018059	03/06/03	PCT		A61K	45/06		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
321	JF	Vaccaro, W.D. et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" <i>Bioorganic & Medicinal Chemistry Ltrs., Oxford, G.B.</i> , 8:313-318 (1998)							
	JG	Vaccaro, W.D. et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", <i>Biogenic & Medicinal Chem. Ltrs. Oxford, G.B.</i> 8:319-322 (1998)							
	JH	H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", <i>Arterioscler, Thromb. Vasc. Biol</i> 21:2032-2038, (Dec. 2001)							
	JI	Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", <i>Chemical Abstracts No. 15</i> , 86 (April 11, 1997)							
	JJ	Otto et al., "Stereochemistry of dehydration and halogenation of α R* and α S* isomeric 3-(α -hydroxybenzyl)-1,4 diphenyl-2 azetidinones", <i>Chemical Abstracts No. 19</i> , 99 (Nov. 7, 1983)							
	JK	T. Durst et al., "Metallation of N-Substituted β -Lactams. A Method of the Introduction of 3-substituents into β -Lactams" <i>Canadian Journal of Chemistry</i> , 50:3196-3201 (1971)							
	JL	Nobuki, O. et al., "Stereoselective syntheses of β -lactam derivatives by ultrasound promoted Reformatskii reaction" <i>Chemical Abstracts No. 106</i> , 17 (April 27, 1987)							
	JM	M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ -Lactones", <i>J. Agric. Food Chem.</i> , 30:920-924 (1982)							
	JN	H. Otto et al. "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidinonen", <i>Liebigs Ann. Chem.</i> 1152-1161 (1983)							
	JO	G. George et al. "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" <i>Tetrahedron Letters</i> , 26:3903-3906 (1985)							
	JP	Hart et al. "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", 26 <i>Tetrahedron Letters</i> , 45:5493-5496 (1985)							
	JQ	Panfil, I. et al. "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" 24 <i>Heterocycles</i> 6:1609-1617 (1986)							
	JR	D. Roger Illingworth, "An Overview of Lipid-Lower Drugs" <i>Drugs</i> 36:63:71 (1988)							
	JS	Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" <i>Circulation</i> 80:1101-1114 (1989)							
	JT	B. Ram et al. "Potential Hypolipidemic agents: Part V", 29B <i>Indian J. Chem.</i> 1134-37 (1990)							
	JU	Schnitzer-Polokoff, R. et al., "Effects of Acyl-CoA: Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" <i>Comp. Biochem. Physiol.</i> 99A:665-670 (1991)							
	JV	Horie, M. et al., "Hypolipidemic effects of NB-598 in dogs" <i>Atherosclerosis</i> 88:183-192 (1991)							
	JW	Baxter, A., "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", <i>The Journal of Biological Chemistry</i> 267:11705-11708 (1992)							
321	JX	Summary Factfile, "Anti-Atherosclerotic Agents" <i>Current Drugs Ltd.</i> (1992)							

Sanhyth 1/22/04



GROUP 1/00

APR 22 2003

RECEIVED

Sheet 4 of 9


RECEIVED

APR 25 2003

TECH CENTER 1600/2900

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01492K	SERIAL NO.: 10/056,680
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT: T. Kosoglou et al.	
(Use several sheets if necessary)			FILING DATE: January 25, 2002	GROUP: 1743
SM	JY	Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tigogenin cellobioside (CP-88818; tiqueside) 1" <i>Journal of Lipid Research</i> 34:377-395 (1993)		
	JZ	Salisbury, B. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" <i>Atherosclerosis</i> 115:45-63 (1995)		
	KA	Clader, J. W. et al., "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Viro Activity" <i>Journal of Medicinal Chemistry</i> 38:1600-1607 (1995)		
	KB	Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" <i>Atherosclerosis</i> pp. 311-315 (1995)		
	KC	Vaccaro, W, et al, "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", <i>Bioorg. & Med. Chem.</i> 6:1429-1437 (1998)		
	KD	G. Wu et al, "A Novel One-Step Diastereo-and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (4/21/99).		
	KE	B. Staels, "New Roles for PPARS in Cholesterol Homeostasis", <i>Trends in Pharmacological Sciences</i> , 22:9 p. 444 (Sept. 2001)		
	KF	Abbott et al, "Tricor® Capsules, Micronized", <i>Physicians Desk Reference</i> , January 8, 2001.		
	KG	M. Feher et al., 1991, <i>Lipids and Lipid Disorders</i> , p.1-87 (1991).		
	KH	M. Ricote et al., "New Roles for PPARs in Cholesterol Homeostasis", <i>Trends in Pharmacological Science</i> , Vol. 22, No. 9 441-443 (2001)		
	KI	C. Dujovne et al, "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", <i>J. Clin., Pharm.</i> 41:1 70-78 (Jan. 2001)		
	KJ	W. Oppolzer et al., "Asymmetric Diels - Alder Reactions, Facile Preparation and Structure of Sulfonamido - Isobornyl Acrylates", <i>Tetrahedron Letters</i> No. 51, 25:5885-5888 (1984).		
	KK	M. Davidson et al., "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", <i>Expert Opinion Investigating Drugs</i> , 11:2663-71, (Nov. 2000)		
	KL	M. Davidson et al., "Colesevelam hydrochloride (cholestagel): a new, potent bileacid sequestrant associated with a low incidence of gastrointestinal effects", <i>159 Arch. Intern. Med.</i> 16 1893-900 (Sept. 1999)		
	KM	I. Wester, "Cholesterol - Lowering effect of plant sterols", <i>Euro. J.Lipid, Sci. Tech.</i> 37-44 (2000).		
	KN	A. Andersson et al., "Cholesterol -lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowering diet", <i>1 European Heart. J. Supplements</i> S80 - S90 (1999)		
	KO	H. Gylling et al, "Reduction of Serum Cholesterol in Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostanol Ester Margarine, 96 <i>Circulation</i> 12 4226-4231 (Dec. 16, 1997)		
	KP	T. Miettinen et al, "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", <i>New England Journal of Med.</i> 333 1308-1312 (Nov. 16, 1995)		
	KQ	T. Bocan et al., "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", <i>Arterioscler Thromb Vasc. Biol.</i> 70-79 (Jan. 2000)		
SM	KR	M. Van Heek et al., "In Vivo Metabolism - Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," 283 <i>J. Pharma and Experimental Therapeutics</i> 1 157-163 (1997)		

Van Heek et al - 1/22/04



GROUP 1700

APR 22 2003

Sheet

RECEIVED

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. APR 17 2003 CV01492K	SERIAL NO.: 10052080
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT T. Kosoglou	
(Use several sheets if necessary)				FILING DATE: January 25, 2002	GROUP: 1743
SM	KS	H. Davis <i>et al.</i> , "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," 151 <i>Atherosclerosis</i> 1:133 (July 2000)			
	KT	L. Nguyen <i>et al.</i> , "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", 10 <i>Atherosclerosis</i> 2, 289-297 (1990)			
	KU	L. Nguyen <i>et al.</i> , "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and dietary sterol restriction," 32 <i>J. Lipid Res.</i> 1941-1948 (1991)			
	KV	M. Cobb <i>et al.</i> , "Sitosterolemia: Opposing Effects of cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," 45 <i>Metabolism</i> 6 673-679 (June 1996)			
	KW	M. Huettinger <i>et al.</i> , "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", 13 <i>Arteriosclerosis and Thrombosis</i> 7 1005-1012 (July 1993).			
	KX	J. Best <i>et al.</i> , "Diabetic Dyslipidaemia", 59 <i>Drugs</i> 5 1101-1111 (May 2000)			
	KY	P. Chong, <i>et al.</i> , "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", 60 <i>Drugs</i> 1 55-93 (July 2000)			
	KZ	M. Brown <i>et al.</i> , "A Receptor - Mediated Pathway for Cholesterol Homeostasis", 232 <i>Science</i> 34-47 (April 4, 1986)			
	LA	L. Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", <i>JACC</i> 257A (Feb. 2000)			
	LB	Medical Economics, Co., Inc., <i>Physician's Desk Reference</i> , 207-208, 2054 (55 th Ed. 2001)			
	LC	K. Fassbender <i>et al.</i> , "Simvastatin Strongly Reduces Levels of Alzheimer's Disease β -Amyloid Peptides A β 42 and A β 40 in vitro and in vivo", <i>PNAs Early Edition</i> , www.phas.org/cgi/doi/10.1073/phas.081620098 (2001)			
	LD	Andrx Announces Results of Alzheimer's Disease Clinical Study", <i>Andrx Corporate Release</i> (April 11, 2001)			
	LE	Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130", <i>US Bancorp Piper</i> , April 12, 2001			
	LF	Statins May Protect Against Alzheimer's Disease; much research needed", <i>Geriatrics</i> February 2001			
	LG	Dementia and Statins", <i>The Lancet</i> March 17, 2001			
	LH	Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers", <i>Reuters</i> April 11, 2001			
	LI	Cholesterol Drugs Ease Alzheimer's Damage; www.usatoday.com April 10, 2001			
	LJ	Lovastatin XL of Use in Alzheimer's? News Edge (May 2, 2001)			
	LK	L. Refolo <i>et al.</i> , "Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model, <i>Neurobiology of Disease</i> 321-331 (2000)			
	LL	D. Kang <i>et al.</i> , "Modulation of Amyloid β -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor - Related Protein Pathway", <i>Journal of Clinical Investigation</i> 106:9, 1159-1166 (Nov. 2000)			
	LM	Y.A. Kesaniewmi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", <i>J. Clin. Invest.</i> 80(2) 578-81 (Aug. 1987)			
	LN	J. Busciglio <i>et al.</i> , "Generation of β -amyloid in the secretory pathway in neuronal and nonneuronal cells", 90 <i>Proc. Nat'l. Acad. Sci. USA</i> , 2092-2096 <i>Neurobiology</i> (March 1993)			
	LO	L. Farrer <i>et al.</i> , "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", <i>Annals of Neurology</i> 25:5, 485-493 (May 1989)			
SM	LP	A. Goate <i>et al.</i> , "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", 349 <i>Nature</i> No. 6311, 704-706 (Feb. 21, 1991)			

Parham 1/22/04



RECEIVED

APR 25 2003

Sheet 6 of

GROUP 17
RECEIVED
APR 22 2003

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900		ATTY. DOCKET NO.: CV01492K	SERIAL NO.: 10/056,680
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: T. Kosoglou et al.	
				FILING DATE: January 25, 2002	GROUP: 1743
84	LQ	D. Mann et al., "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", 89 <i>J. Neuro. Sci.</i> , 169-179 (Feb. 1989)			
	LR	G. McKhann et al., "Clinical Diagnosis of Alzheimer's Disease", 34 <i>Neurology</i> No. 7, 939-944 (July 1984)			
	LS	D. Selokoe, "Alzheimer's Disease: Genotypes, Pheontype and Treatments", 275 <i>Science</i> , 630-631 (Jan. 31, 1997)			
	LT	C. Van Duijn, et al., "Familiial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", 20 <i>Int'l J. Epidemiology</i> No. 2 (Suppl. 2), 513-520 (1991)			
	LU	T Nagahara et al., "Dibasic (Amidcinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", <i>J. Med. Chem</i> 37:1200-1207 (1994)			
	LV	Mellott et al., "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistasin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <i>Circulation Research</i> , 70:1152-1160 (1992)			
	LW	Sitko et al., "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", <i>Circulation</i> , 85:805-815 (1992)			
	LX	Seymour et al., 1994, <i>Biochemistry</i> , 33:3949-3959			
	LY	Markwardt, 1994, <i>Thrombosis and Hemostasis</i> , 72:477-479			
	LZ	Mendall et al., "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", <i>BMJ</i> , 312:1061-1065 (April 27, 1996)			
	MA	Ridker P. et al., "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", 46 <i>J. Investig. Med.</i> , 8:391-395 (1998)			
	MB	L. Gruberb, 2000, "Inflammatory Markers in Acute Coronary Syndromes: C-reactive protein (CRP) and Chlamydia", <i>American Heart Association Scientific Sessions</i>			
	MC	Waters, D. et al., "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", <i>Circulation</i> , 82:1940-1953 (1990)			
	MD	Fleckenstein, 1985, <i>Cir. Res.</i> Vol 52 (Suppl. 1) 3-16			
	ME	Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", <i>John Wiley, New York</i> , pp. 286-313			
	MF	McCall, D., 1985, "Curr. Pract. Cardiol. Vol. 10, 1-11			
	MG	Remington 1995, "The Science and Practice of Pharmacy, (19 th Ed. 1995) p. 963			
	MH	M. Chistie et al., "Early - Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", 276 <i>J. Biol. Chem.</i> No. 24; 21562-70 (June 15, 2001)			
	MI	C. Janus et al., "A β Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", 408 <i>Nature</i> 21/28; 979-982 (Dec. 2000)			
	MJ	Manual of Laboratory Operations, "Lipid Research Clinics Program Report, Washington, D.C., U.S. Dept. of Health, Education and Welfare Publication; 1:75-628 (1974)			
	MK	Steiner, PM et al., "Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract], <i>J. Clin. Chem. Clin. Bichem</i> ; 19:850 (1981)			
	ML	Steele WG, et al., "Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique, 22 <i>Clin. Chem.</i> ; 1:98-101 (1976)			
84	MM	Salen et al., "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Choelsterol Syntheses in Sitosterolemia with Xanthomatosis", <i>J. Lipd Res.</i> ; 30:1319-1330 (1989)			

Sanbury 1/22/04

**RECEIVED**

APR 25 2003

Sheet 7 of 9**GROUP 1700**

FORM PTO-1472		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01492K	SERIAL NO.: 10/056,680
INFORMATION DISCLOSURE BY APPLICANT		APPLICANT: T. Kosoglou et al.			
(Use several sheets if necessary)		FILING DATE: January 25, 2002		GROUP: 1743	
321	MN	Lutjohann et al., "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", <i>J. Lipid Res.</i> ; 36:8 ; 1763-1773 (1995)			
	MO	Zhang et al., "Calpain Inhibitor I Increases B- Amyloid Peptide by Inhibiting the Degradation of the Substrate of γ - Secretase" 274 J. Biol. Chem. , 13:8966-8972 (1999)			
	MP	Zhang et al., "Biochemical Characterization of the γ -Secretase Activity that Produces B-Amyloid Peptides", <i>Biochemistry</i> 40:5049-5055 (2001)			
	MQ	Ida et al., "Analysis of Heterogeneous BA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", 271 J. Biol. Chem. ; 37:22908-22914 (1996)			
	MR	Lichtlen, P.R. et al., 1990, <i>Lancet</i> ; 335:1109-1113			
	MS	Bays et al., "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies", <i>Clinical Therapeutics</i> , 23:1209-1230 (2001)			
	MT	E. Leitersdorf et al., "Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management", <i>European Heart Journal Supplement</i> , 3:E17-E23 (June 2001)			
	MU	Bauer et al., "Ezetimibe Does not Affect the Pharmacokinetics or Pharmacodynamics of Warfarin", <i>Clinical Pharmacology and Therapeutics</i> , 69:2 p5 (Mar. 6-10, 2001)			
	MV	Keung et al., "Ezetimibe Does Not Affect the Pharmacokinetics of oral Contraceptives", <i>Clinical Pharmacology and Therapeutics</i> , 69:2 p55 (Mar. 6-10, 2001)			
	MW	Kosoglou et al., "Pharmacodynamic interaction between fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs 72nd EAS Congress</i> , p. 38 (May 21-23, 2001)			
	MX	T. Kosoglou et al., "Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects On Apo CII and LDL Subfractions", <i>Posters 11. Lipid Lowering Drugs/Novel, 72nd EAS Congress</i> , p. 89 (May 21-23, 2001)			
	MY	L. Reyderman et al., "Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Gemfibrozil", Presented at XIV Int'l Symp. on Drugs Affecting Lipid Metabolism (DALM) N.Y. (Sept. 9-12, 2001)			
	MZ	P. Statkevich et al., "Ezetimibe Does Not Affect the Pharmacokinetics and Pharmacodynamics of Glipizide", <i>Clinical Pharmacology & Therapeutics</i> , 69:67 (March 6-10, 2001)			
	NA	Knopp et al., "Effect of Ezetimibe on Serum Concentrations of Lipid-Soluble Vitamins", <i>Posters 11. Lipid Lowering Drug/Novel 72nd EAS Congress</i> , p. 90 (May 21-23, 2001)			
	NB	Kosoglou et al., "Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs, 72nd EAS Congress</i> , p. 38 (March 6-10, 2001)			
	NC	Bays et al., "Low-Density Lipoprotein Cholesterol Reduction By SCH 58235 (Ezetimibe), A Novel Inhibitor of Intestinal Cholesterol Absorption, in 243 Hypercholesterolemic Subjects: Results of a Dose-Response Study", <i>XII International Symposium on Atherosclerosis, Stockholm, Sweden (June 25-29, 2000)</i>			
	ND	Castaner et al., "Ezetimibe - Hypolipidemic Cholesterol Absorption Inhibitor", <i>Drugs of the Future</i> , 25(7):679-685 (2000)			
	NE	Lipka et al., "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by Ezetimibe (SCH 58235): Pooled Analysis of Two Phase II Studies", <i>American College of Cardiology Annual Meeting, Anaheim, CA (March 12-15, 2000)</i>			
81	NF	Van Heek et al., "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663", <i>British Journal of Pharmacology</i> , 129:1748-1754 (2000)			

Van Heek - 1/22/04



RECEIVED

APR 25 2003

Sheet 8 of 9

GROUP 1700
RECEIVED
APR 22 2003

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01492K	SERIAL NO.: 10/056,680
INFORMATION DISCLOSURE BY APPLICANT		APPLICANT: T. Kosoglou et al.			
(Use several sheets if necessary)		FILING DATE: January 25, 2002		GROUP: 1743	
SH	NG	Van Heek et al., 2000, "The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically", <i>XII International Symposium of Atherosclerosis, Stockholm Sweden (June 25-29, 2000)</i>			
	NH	Iannucci et al., "Metabolism of SCH 58235 in the Human, Rat and Dog", <i>47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX (June 13-17, 1999)</i>			
	NI	Reiss et al., "An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors", <i>Bioorganic & Medicinal Chemistry</i> , 7:2199-2202 (1999)			
	NJ	Rosenblum et al., "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", <i>J. Med. Chem.</i> 41:973-980 (1998)			
	NK	Vaccaro et al., "Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8:313-318 (1998)			
	NL	Zaks et al., "Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235", <i>Applied Biochemistry and Biotechnology</i> , 73:205-214 (1998)			
	NM	W. Insull et al., "Postmenopausal Hypercholesterolemic Women Derive Additive Benefit from Raloxifene and Simvastatin on Lipid Parameters", <i>World Heart Federation 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke - Abstract Book</i> , p. 35 (June 12-15, 2002)			
	NN	L. Simons et al., 2002, "Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia: Efficacy and safety in patients with Type 2 diabetes mellitus", presented at the 38 th Annual Meeting of the EASD, September 1-5, 2002			
	NO	C. Allain et al, 1974, "Enzymatic Determination of Total Serum Cholesterol", <i>Clinical Chemical</i> , 20:470-475			
	NP	R. Mayrhofer et al., 1980, "Simple-Preparation of 3-Benzylidene-2-azetidinones", <i>Synthesis</i> , 247-248			
	NQ	Burrier, R.E. et al., 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", <i>Biochemical Pharmacology</i> 47:1545-1551			
	NR	Burrier, R.E. et al., 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibitor on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 272:156-163			
	NS	E.F. Binder et al., "Effects of Hormone Replacement Therapy on Serum Lipids in Elderly Women. A Randomized, Placebo-Controlled Trial", <i>134 Ann. Intern. Med.</i> 9:754-760 (May 1, 2001)			
	NT	MR Haymart et al., "Optimal Management of Dyslipidemia in Women and Men", <i>2 J. Gend. Specif. Med.</i> 6:37-42 (Nov. - Dec. 1997)			
	NU	"Framingham Heart Study Analysis Reveals Some Primary Prevention Subgroups Are Being Overlooked", <i>Heartwire</i> (April 12, 2001)			
	NV	"Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third Report of the National Cholesterol Education Program (NCEP)", <i>NIH Publication No. 01-3670</i> (May 2001)			
	NW	Van Heek et al., "Ezetimibe, A Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters", <i>50 Diabetes</i> 1330-1335 (June 2001)			
	NX	"Additional Statins Show Anti-Inflammatory Effect", <i>103 Circulation</i> 1933-35 (April 17, 2001)			
	NY	H. Hauser, et al, "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine", <i>Biochemistry</i> 37:17843-17850, 1998			
	NZ	G. Salen, et al., "Sitosterolemia", <i>Journal of Lipid Research</i> 33:945-955, 1992			
SH	OA	Stedman's Medical Dictionary, 27 th Edition, pg. 1381			

Pauph 1/22/04

Sheet 9 of 9

FORM PTO-1049		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01492K	SERIAL NO.: 10/056,680
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: T. Kosoglou et al.	
				FILING DATE: January 25, 2002	
SH	OB	P.F. Belamarich <i>et al.</i> , "Response to Diet and Cholestyramine in a Patient with Sitosterolemia", <i>Pediatrics</i> , 977-981, (December 1990)			
SH	OC	G. Salen <i>et al.</i> , "Lethal Atherosclerosis Associated With Abnormal Plasma and Tissue Sterol Composition in Sitosterolemia With Xanthomatosis", <i>Journal of Lipid Research</i> , 1126-1133, (September 1985)			
SH	OD	G.R. Thompson <i>et al.</i> , "Novel Lipid-Regulating Drugs, Exp. Opin. Invest. Drugs, 9(11):2619-2628, 2000			
[Signature]				DATE CONSIDERED 1/22/04	

32205

RECEIVED

APR 25 2003

TECH CENTER 1600/2900

GROUP 1700
APR 22 2003
RECEIVED



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01492KSERIAL NO.:
10/056,680INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
T. Kosoglou et al.FILING DATE:
January 25, 2002GROUP:
1743

(Use several sheets if necessary)


U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
5H	AA	US2002/0132855	09/19/02	Nelson, et al.			
	AB	US2002/0137689	09/26/02	Glombik et al.			
	AC	US2002/0128253	09/12/02	Glombik et al.			
	AD	US2002/0039774	04/04/02	Kramer et al.			
	AE	US2002/0128252	09/12/02	Glombik et al.			
	AF	10/057,534	01/25/02	Harry R. Davis et al.			
	AG	10/057,646	01/25/02	Harry R. Davis et al.			
	AH	10/057,629	01/25/02	Harry R. Davis			
	AI	10/154,106	05/22/02	Harry R. Davis et al.			
	AJ	10/057,323	01/25/02	Harry R. Davis et al.			
	AK	10/136,968	05/01/02	Wing-Kee Philip Cho et al.			
	AL	10/057,339	01/25/02	Teddy Kosoglou et al.			
	AM	10/247,032	01/25/02	Harry R. Davis			
	AO	10/247,099	09/19/02	Harry R. Davis et al.			
	AP	10/247,085	09/19/02	John T. Strony			
	AQ	10/247,095	09/19/02	Harry R. Davis			
	AR	10/246,996	09/19/02	Alexandre P. Lebeaut et al.			
	AS	10/247,397	09/19/02	Harry R. Davis et al.			
5H	AT	10/166,942	06/11/02	Anima Ghosal et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
							YES NO
5H	AU	BE 884722 A	12/01/80	BELGIUM	C07D	AG1K	X(abs.)
	AV	CA 2253769	11/29/99	CANADA	A61K	31/22	
	AW	DE 2046823 A	03/30/72	GERMANY	C07C		X(abs.)
	AX	DE 2521113 A	03/18/76	GERMANY	C07C	87/34	X(abs.)
	AY	EP 0002151 A1,B1	05/30/79	EUROPE	C07C	69/67	
	AZ	EP 0010299 B1	02/15/84	EUROPE	A61K	45/06	
	BA	EP 0179559 A2	04/30/86	EUROPE	C07D	405/06	
	BB	EP 0199630 A1	10/29/86	EUROPE	C07D	205/08	
	BC	EP 0199630 B1	09/19/90	EUROPE	C07D	205/08	
	BD	EP 0264231 A1	04/20/88	EUROPE	C07D	205/08	
	BE	EP 0266896 B1	05/11/88	EUROPE	C07D	471/04	
	BF	EP 0274873 B1	07/20/88	EUROPE	C07K	11/00	
	BG	EP 0288973 B1	11/02/88	EUROPE	C07D	417/06	
	BH	EP 0311366 B1	04/12/89	EUROPE	C07D	471/04	
	BI	EP 0333268 A1	09/20/89	EUROPE	C07F	7/18	
	BJ	EP 0337549 A1	10/18/89	EUROPE	C07D	205/08	
	BK	EP 0337549 B1	10/04/95	EUROPE	C07D	205/08	
	BL	EP 0365364 A2	04/25/90	EUROPE	C07D	205/08	
	BM	EP 0369686 A1	05/23/90	EUROPE	C07D	463/00	
	BN	EP 0375527 A1	06/27/90	EUROPE	C07D	205/08	X(abs.)
	BO	EP 0401705 A3	12/12/90	EUROPE	A61K	31/66	
	BP	EP 0415487 A2	03/06/91	EUROPE	C07D	205/08	
	BQ	EP 0455042 A1	11/06/91	EUROPE	A61K	31/19	
	BR	EP 0457514 A1	11/21/91	EUROPE	A61K	45/06	
	BS	EP 0457514 B1	08/21/96	EUROPE	A61K	45/06	
	BT	EP 0461548 A3	12/18/91	EUROPE	A61K	31/365	
5H	BU	EP 0462667 A2	12/27/91	EUROPE	C07D	205/08	

Sahyati 1/22/04



FORM O-1449


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01492KSERIAL NO.:
10/056,680INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
T. Kosoglou et al.FILING DATE:
January 25, 2002GROUP:
1743

(Use several sheets if necessary)

52	BV	EP 0475148 A1	03/18/92	EUROPE	A61K	31/215		
	BW	EP 0475755 B1	03/18/92	EUROPE	C07D	403/06		
	BX	EP 0481671 A1	04/22/92	EUROPE	C07D	205/08		
	BY	EP 0482498 A3	04/29/92	EUROPE	A61K	31/66		
	BZ	EP 0524595 A1	01/27/93	EUROPE	C07D	205/08		
	CA	EP 0720599 B1	07/10/96	EUROPE	C07D	205/08		
	CB	EP 0793958 A2	09/10/97	EUROPE	A61K	9/16	X(abs.)	
	CC	EP 0814080 A1	12/29/97	EUROPE	C07D	267/14		
	CD	EP 0904781 A2	03/31/99	EUROPE	A61K	31/215		
	CE	EP 1048295 A2	11/02/00	EUROPE	A61K	31/216		
	CF	FR 1103113	10/31/55	FRANCE				X
	CG	FR 2779347	12/10/97	FRANCE	A61	031/215	X(abs.)	
	CH	GB 861367	02/22/61	GB	A61K			
	CI	GB 902658	08/09/62	GB	C07D			
	CJ	GB 1415295	11/26/75	GB	C07C	59/26		
	CK	GB 2329334 A	03/24/99	GB	A61K	45/00		
	CL	JP 028057	10/01/81	JAPAN			X(abs.)	
	CM	JP 121479	12/10/86	JAPAN			X(abs.)	
	CN	JP 136485	05/26/81	JAPAN			X(abs.)	
	CO	JP 180212	03/24/86	JAPAN			X(abs.)	
	CP	JP 219681	04/14/87	JAPAN			X(abs.)	
	CQ	JP 5194209 A	08/03/93	JAPAN	A61K	031/22	X(abs.)	
	CR	JP 5239020 A	1993	JAPAN	C07D	205/08	X(abs.)	
	CS	JP 4054182 A	1992	JAPAN	12P	017/16	X(abs.)	
	CT	JP 63017859 A	1988	JAPAN	7D	205/08	X(abs.)	
	CU	JP 4266869 A	1992	JAPAN	7D	205/08	X(abs.)	
	CV	JP 4356195 A	1993	JAPAN			X(abs.)	
	CW	JP 4356495	12/10/92	JAPAN			X(abs.)	
	CX	JP 5058993 A	1993	JAPAN			X(abs.)	
	CY	JP 61280295 A	1987	JAPAN			X(abs.)	
	CZ	JP 95051558 B2	06/05/95	JAPAN	C07D	205/08	X(abs.)	
	DA	JP 91068020	10/25/91	JAPAN	C07D	205/08	X(abs.)	
	DB	JP 94047573	06/22/94	JAPAN	C07D	205/08	X(abs.)	
	DC	WO 82/01649	05/27/82	PCT	A61K	9/52	X(abs.)	
	DD	WO 87/04429	07/30/87	PCT	C07D	205/08		
	DE	WO 88/04656	06/30/88	PCT	C07D	405/04		
	DF	WO 88/05296	07/28/88	PCT	A61K	31/365		
	DG	WO 91/03249	03/21/91	PCT	A61K	31/785	X(abs.)	
	DH	WO 92/13837	08/20/92	PCT	C07D	205/085		
	DI	WO 93/02048	02/04/93	PCT	C07D	205/08		
	DJ	WO 93/07167	04/15/93	PCT	C07J	71/00		
	DK	WO 93/11150	06/10/93	PCT	C07J	71/00		
	DL	WO 94/00480	01/06/94	PCT	C07J	71/00		
	DM	WO 94/14433	07/07/94	PCT	A61K	31/395		
	DN	WO 94/17038	08/04/94	PCT	C07D	205/12		
	DO	WO 94/20535	09/15/94	PCT	C07K	13/00		
	DP	WO 95/04533	02/16/95	PCT	A61K	31/445		
	DQ	WO 95/06470	03/09/95	PCT	A61K	31/435		
	DR	WO 95/08532	03/30/95	PCT	C07D	205/08		
	DS	WO 95/18143	07/6/95	PCT	C07J	71/00		
53	DT	WO 95/26334	10/05/95	PCT	C07D	205/08		

Kosoglou 1/22/04

RECEIVED
JAN 23 2003
TC 1700RECEIVED
JAN 24 2003
TECH CENTER 1600/2900



FORM PTO-1449


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01492KSERIAL NO.:
10/056,680INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
T. Kosoglou et al.FILING DATE:
January 25, 2002GROUP:
1743

(Use several sheets if necessary)

32	DU	WO 95/28919	11/02/95	PCT	A61K	31/19	X(abs.)	
	DV	WO 96/00288	01/04/96	PCT	C12N	15/12		
	DW	WO 96/09827	04/04/96	PCT	A61K	31/58		
	DX	WO 96/16037	05/30/96	PCT	C07D	205/08		
	DY	WO 96/19987	07/04/96	PCT	A61K	31/35		
	DZ	WO 96/40255	12/19/96	PCT	A61K	45/06		
	EA	WO 97/16455	05/09/97	PCT	C07H	3/04		
	EB	WO 97/18304	05/22/97	PCT	C12N	15/00		
	EC	WO 97/25042	07/17/97	PCT	A61K	31/42		
	ED	WO 97/28149	08/07/97	PCT	C07D	307/79		
	EE	WO 97/31907	09/04/97	PCT	C07D	263/56		
	EF	WO 97/35576	10/02/97	PCT	A61K	31/44		
	EG	WO 97/46238	12/11/97	PCT	A61K	31/245		
	EH	WO 98/01100	01/15/98	PCT	A61K			
	EI	WO 98/05331	02/12/98	PCT	A61K	31/45		
	EJ	WO 98/14179	04/09/98	PCT	A61K	9/50		
	EK	WO 98/31360	07/23/98	PCT	A61K	31/19		
	EL	WO 98/31361	07/23/98	PCT	A61K	31/215	X(abs.)	
	EM	WO 98/31366	07/23/98	PCT	A61K	31/445		
	EN	WO 98/43081	10/01/98	PCT	G01N	33/50		
	EO	WO 98/46215	10/22/98	PCT	A61K	9/20		
	EP	WO 98/47518	10/29/98	PCT	A61K	31/715		
	EQ	WO 98/57652	12/23/98	PCT	A61K	31/785		
	ER	WO 99/04815	04/02/99	PCT	A61K	45/00	X(abs.)	
	ES	WO 99/06035	02/11/99	PCT	A61K	31/00		
	ET	WO 99/06046	02/11/99	PCT	A61K	31/455		
	EU	WO 99/09967	03/04/99	PCT	A61K	31/00		
	EV	WO 99/12534	03/18/99	PCT	A61K	31/17	X(abs.)	
	EW	WO 99/11260	03/11/99	PCT	A61K	31/40		
	EX	WO 99/15159	04/01/99	PCT	A61K	31/00		
	EY	WO 99/15520	04/01/99	PCT	C07D	319/20	X(abs.)	
	EZ	WO 99/18072	04/15/99	PCT	C07D	205/08		
	FA	WO 99/20275	04/29/99	PCT	A61K	31/47		
	FB	WO 99/20614	04/29/99	PCT	C07D	265/36		
	FC	WO 99/29300	06/17/99	PCT	A61K	9/107		
	FD	WO 99/38498	08/05/99	PCT	A61K	31/00		
	FE	WO 99/38845	08/05/99	PCT	C07D	213/65		
	FF	WO 99/38850	08/05/99	PCT	C07D	237/32		
	FG	WO 99/46232	09/16/99	PCT	C07C	62/34	X(abs.)	
	FH	WO 99/47123	09/23/99	PCT	A61K	9/16		
	FI	WO 99/48488	09/30/99	PCT	A61K	31/00		
	FJ	WO 99/66929	12/29/99	PCT	A61K	31/405		
	FK	WO 99/66930	12/29/99	PCT	A61K	31/405		
	FL	WO 00/04011	01/27/00	PCT	C07D	319/06		
	FM	WO 00/07617	02/17/00	PCT	A61K	38/26		
34	FN	WO 00/16749	03/30/00	PCT	A61K	9/16	X(abs.)	

Signature 1/22/04

RECEIVED
JAN 23 2003
TECH CENTER 1600/2900
JAN 24 2003
RECEIVED



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

SERIAL NO.:

CV01492K

10/056,680

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

T. Kosoglou et al.

FILING DATE:

January 25, 2002

GROUP:

1743

(Use several sheets if necessary)

37	FO	WO 00/18395	04/06/00	PCT	A61K	31/215		
	FP	WO 00/20623	04/13/00	PCT	C12P	41/00		
	FQ	WO 00/23415	04/27/00	PCT	C07C	69/734		
	FR	WO 00/23416	04/27/00	PCT	C07C	69/734		
	FS	WO 00/23425	04/27/00	PCT	C07D	209/80		
	FT	WO 00/23445	04/27/00	PCT	C07D	471/12		
	FU	WO 00/23451	04/27/00	PCT	C07D	487/14		
	FV	WO 00/28981	05/25/00	PCT	A61K	31/00		
	FW	WO 00/31548	06/02/00	PCT	G01N	33/68		
	FX	WO 00/32189	06/08/00	PCT	A61K	31/415		
	FY	WO 00/34240	06/15/00	PCT	C07D	205/08		
	FZ	WO 00/37057	06/29/00	PCT	A61K	9/48		
	GA	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)	
	GB	WO 00/38721	07/06/00	PCT	A61K	45/06		
	GC	WO 00/38722	07/06/00	PCT	A61K	45/06		
	GD	WO 00/38723	07/06/00	PCT	A61K	45/06		
521	GE	WO 00/38724	07/06/00	PCT	A61K	45/06		

DATE CONSIDERED

1/22/04

30343x

RECEIVED
JAN 24 2003
TECH CENTER 1600/2900



Electronic Information Disclosure Statement

RECEIVED
SEP 16 2002
TECH CENTER 1600/2800

COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS

Application:



10/056680

Confirmation: 9993

Applicant(s): Teddy Kosoglou

Docket

CV01492K

Number:

Group Art

1743

Unit:

Examiner:

RECEIVED
AUG 27 2002
TC 1700

(2809194 or 3108097 or 3152173 or 3267104 or 3399192 or 3692895 or 4148923 or 4239763 or 4567195 or 4626549 or 4654362 or 4680289 or 4937267 or 5093365 or 5106833 or 5110730 or 5120713 or 5278176 or 5358852 or 5385885 or 5703188 or 5994554 or 6008237 or 6028109 or 6033656 or 6040147 or 6121319 or 6127424 or 6140354 or 6147090 or 6147109 or 6147250 or 6159997 or 6162805 or 6166049 or 6174665 or 6180138 or 6180625 or 6180660 or 6191117 or 6191159 or 6200998 or 6207697 or 6207699 or 6207822 or 6214831 or 6235706 or 6245743 or 6248781 or 6251852).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
OH	P01	2809194	1957-10-08		Novello		


Patented 1/22/04

82	P02	3108097	1963-10-22	Ugi
	P03	3152173	1964-10-06	Ehrhart
	P04	3267104	1966-08-16	Hermans
	P05	3399192	1968-08-27	Regnier
	P06	3692895	1972-09-19	Nelson
	P07	4148923	1979-04-10	Giudicelli
	P08	4239763	1980-12-16	Milavec
	P09	4567195	1986-01-28	Schwarz
	P10	4626549	1986-12-02	Molloy
	P11	4654362	1987-03-31	Lommen
	P12	4680289	1987-07-14	Applezweig
	P13	4937267	1990-06-26	Holloway
	P14	5093365	1992-03-03	Berge
	P15	5106833	1992-04-21	Broze
	P16	5110730	1992-05-05	Edgington
	P17	5120713	1992-06-09	Mugica
	P18	5278176	1994-01-11	Lin
	P19	5358852	1994-10-25	Wu
	P20	5385885	1995-01-31	Gasic
	P21	5703188	1997-12-30	Mandeville
	P22	5994554	1999-11-30	Kliwer
	P23	6008237	1999-12-28	Sahoo
	P24	6028109	2000-02-22	Wilson
	P25	6033656	2000-03-07	Mikami
	P26	6040147	2000-03-21	Ridker
	P27	6121319	2000-09-19	Somers
	P28	6127424	2000-10-03	Martin
	P29	6140354	2000-10-31	Dax
82	P30	6147090	2000-11-14	DeNinno


Anthony 1/22/04

P31	6147109	2000-11-14	Liao
P32	6147250	2000-11-14	Somers
P33	6159997	2000-12-12	Tsujita
P34	6162805	2000-12-19	Hefti
P35	6166049	2000-12-26	Smith
P36	6174665	2001-01-16	Dullien
P37	6180138	2001-01-30	Engh
P38	6180625	2001-01-30	Persson
P39	6180660	2001-01-30	Whitney
P40	6191117	2001-02-20	Kozachuk
P41	6191159	2001-02-20	Pinto
P42	6200998	2001-03-13	Sahoo
P43	6207697	2001-03-27	Han
P44	6207699	2001-03-27	Rothman
P45	6207822	2001-03-27	Thiruvengadam
P46	6214831	2001-04-10	Yokoo
P47	6235706	2001-05-22	Gould
P48	6245743	2001-06-12	Marlowe
P49	6248781	2001-06-19	Jeppesen
P50	6251852	2001-06-26	Gould

Signature

Examiner Name	Date
	1/72/07

Electronic Information Disclosure Statement



RECEIVED
SEP 16 2002
TECH CENTER 1600/2900

COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS

Application:



10/056680

Confirmation: 9993

Applicant(s): Teddy Kosoglou

Docket

CV01492K

Number:

Group Art

1743

Unit:

Examiner:

RECEIVED
AUG 27 2002
TC 1700

search string: (5827536 or 5827541 or 5831091 or 5843984 or 5846966 or 5847008 or 5847115 or 5851553 or 5856473 or 5858409 or 5859051 or 5862999 or 5866163 or 5869098 or 5871781 or 5880148 or 5883109 or 5886171 or 5919672 or 5925333 or 5952003 or 5952321 or 5959123 or 5972389 or 5976570 or 5985936 or 5990102 or 5998441 or 6027747 or 6043257 or 6056975 or 6057342 or 6063764 or 6066653 or 6071899 or 6074670 or 6080767 or 6080778 or 6084082 or 6090830 or 6090839 or 6093812 or 6096883 or 6099865 or 6103705 or 6110493 or 6117429 or 6133001 or 6139873 or 6143885).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
61	P01	5827536	1998-10-		Laruelle		

Copy 4 1/22/04


			27		
<i>W</i>	P02	5827541	1998-10-27		Yarwood
	P03	5831091	1998-11-03		Ohmizu
	P04	5843984	1998-12-01		Clay
	P05	5846966	1998-12-08		Rosenblum
	P06	5847008	1998-12-08		Doebber
	P07	5847115	1998-12-08		Iwasaki
	P08	5851553	1998-12-22		Myers
	P09	5856473	1999-01-05		Shankar
	P10	5858409	1999-01-12		Karetny
	P11	5859051	1999-01-12		Adams
	P12	5862999	1999-01-26		Czekai
	P13	5866163	1999-02-02		Myers
	P14	5869098	1999-02-09		Misra
	P15	5871781	1999-02-16		Myers
	P16	5880148	1999-03-09		Edgar
	P17	5883109	1999-03-16		Gregg
	P18	5886171	1999-03-23		Wu
<i>SH</i>	P19	5919672	1999-07-06		Homann
			1999-07-		

P20	5925333	20		Krieger
P21	5952003	1999-09-14		Guentensberger
P22	5952321	1999-09-14		Doherty
P23	5959123	1999-09-28		Singh
P24	5972389	1999-10-26		Shell
P25	5976570	1999-11-02		Greaves
P26	5985936	1999-11-16		Novak
P27	5990102	1999-11-23		Hickey
P28	5998441	1999-12-07		Palkowitz
P29	6027747	2000-02-22		Terracol
P30	6043257	2000-03-28		Dominguez
P31	6056975	2000-05-02		Mitra
P32	6057342	2000-05-02		Fevig
P33	6063764	2000-05-16		Creasey
P34	6066653	2000-05-23		Gregg
P35	6071899	2000-06-06		Hickey
P36	6074670	2000-06-13		Stamm
P37	6080767	2000-06-27		Klein
P38	6080778	2000-06-27		Yankner
		2000-07-		

Adhithan 1/22/04

54	P39	6084082	04		Ravikumar
	P40	6090830	2000-07-18		Myers
	P41	6090839	2000-07-18		Adams
	P42	6093812	2000-07-25		Thiruvengadam
	P43	6096883	2000-08-01		Wu
	P44	6099865	2000-08-08		Augello
	P45	6103705	2000-08-15		Uzan
	P46	6110493	2000-08-29		Guentensberger
	P47	6117429	2000-09-12		Bucci
	P48	6133001	2000-10-17		Homann
	P49	6139873	2000-10-31		Hughes
52	P50	6143885	2000-11-07		Choi

Signature

Examiner Name	Date
	1/22/04



Electronic Information Disclosure Statement

COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS

Application:



10/056680

Confirmation: 9993

Applicant(s): Teddy Kosoglou

Docket

CV01492K

Number:

Group Art Unit: 1743

Examiner:

search string: (6262042 or 6262047 or 6262098 or 6242605 or 6277584 or 6316029 or RE37721 or H0001286).pn.

RECEIVED
AUG 27 2002
TC 1700

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents


init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
for	P01	6262042	2001-07-17		Cook		
for	P02	6262047	2001-07-17		Zhu		
for	P03	6262098	2001-07-17		Huebner		

Conkyth 1/22/04

sm	P04	6242605	2001-06-05		Raveendranath
	P05	6277584	2001-08-21		Chu
	P06	6316029	2001-11-13		Jain
	P07	RE37721	2002-05-28		Rosenblum
sm	P08	H0001286	1994-02-01		Eisman

Signature

Examiner Name	Date
<i>Andy H.</i>	<i>1/22/04</i>



Electronic Information Disclosure Statement

RECEIVED
SEP 16 2002
TECH CENTER 1600/2000

COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS

Application:



10/056680

Confirmation: 9993

Applicant(s): Teddy Kosoglou

Docket

CV01492K

Number:

Group Art

1743

Unit:

Examiner:

RECEIVED
AUG 28 2002
TC 1700

search string:

(5567439 or 5576014 or 5587172 or 5587180 or 5591456 or 5593971 or 5595761 or 5607697 or 5612353 or 5612367 or 5612378 or 5618707 or 5622719 or 5622985 or 5624920 or 5627176 or 5631023 or 5631365 or 5633246 or 5635210 or 5639475 or 5639739 or 5656624 or 5661145 or 5674893 or 5688785 or 5688787 or 5688990 or 5691375 or 5698527 or 5698548 or 5703234 or 5709886 or 5718388 or 5728827 or 5734077 or 5739321 or 5744467 or 5747001 or 5753254 or 5756470 or 5759865 or 5767115 or 5776491 or 5807576 or 5807577 or 5807578 or 5807834 or 5808056 or 5817806).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
SH	P01	5567439	1996-10-22		Myers		



Signature 1/22/04

gm	P02	5576014	1996-11-19		Mizumoto
	P03	5587172	1996-12-24		Cherukuri
	P04	5587180	1996-12-24		Allen
	P05	5591456	1997-01-07		Franson
	P06	5593971	1997-01-14		Tschollar
	P07	5595761	1997-01-21		Allen
	P08	5607697	1997-03-04		Alkire
	P09	5612353	1997-03-18		Ewing
	P10	5612367	1997-03-18		Timko
	P11	5612378	1997-03-18		Tianbao
	P12	5618707	1997-04-08		Homann
	P13	5622719	1997-04-22		Myers
	P14	5622985	1997-04-22		Olukotun
	P15	5624920	1997-04-29		McKittrick
	P16	5627176	1997-05-06		Kirkup
	P17	5631023	1997-05-20		Kearney
	P18	5631365	1997-05-20		Rosenblum
	P19	5633246	1997-05-27		McKittrick
	P20	5635210	1997-06-03		Allen
	P21	5639475	1997-06-17		Bettman
	P22	5639739	1997-06-17		Dominguez
	P23	5656624	1997-08-12		Vaccaro
	P24	5661145	1997-08-26		Davis
	P25	5674893	1997-10-07		Behounek
	P26	5688785	1997-11-18		Vaccaro
	P27	5688787	1997-11-18		Burnett
	P28	5688990	1997-11-18		Shankar
	P29	5691375	1997-11-25		Behounek
gm	P30	5698527	1997-12-16		Kim

Shy 1/22/04

P31	5698548	1997-12-16		Dugar
P32	5703234	1997-12-30		Iwasaki
P33	5709886	1998-01-20		Bettman
P34	5718388	1998-02-17		Czekai
P35	5728827	1998-03-17		Kannapan
P36	5734077	1998-03-31		Regnier
P37	5739321	1998-04-14		Wu
P38	5744467	1998-04-28		McKittrick
P39	5747001	1998-05-05		Wiedmann
P40	5753254	1998-05-19		Khan
P41	5756470	1998-05-26		Yumibe
P42	5759865	1998-06-02		Bruns
P43	5767115	1998-06-16		Rosenblum
P44	5776491	1998-07-07		Allen
P45	5807576	1998-09-15		Allen
P46	5807577	1998-09-15		Ouali
P47	5807578	1998-09-15		Acosta-Cuello
P48	5807834	1998-09-15		Morehouse
P49	5808056	1998-09-15		Amato
P50	5817806	1998-10-06		Rossi

Signature

Examiner Name	Date
	

Electronic Information Disclosure Statement



COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS

RECEIVED
SEP 16 2002
TECHNICAL 1600-2400

Application:



10/056680

Confirmation: 9993

Applicant(s): Teddy Kosoglou

Docket

CV01492K

Number:

Group Art

1743

Unit:

Examiner:

RECEIVED
AUG 26 2002
TC 1700

search string: (3716583 or 3781328 or 3948973 or 4072705 or 4075000 or 4144232 or 4178695 or 4179515 or 4235896 or 4250191 or 4260743 or 4304718 or 4375475 or 4443372 or 4444784 or 4472309 or 4479900 or 4500456 or 4534786 or 4564609 or 4576748 or 4576749 or 4576753 or 4581170 or 4595532 or 4602003 or 4602005 or 4614614 or 4616047 or 4620867 or 4633017 or 4642903 or 4675399 or 4680391 or 4739101 or 4778883 or 4784734 or 4794108 or 4800079 or 4803266 or 4834846 or 4814354 or 4834846 or 4871752 or 4876365 or 4879301 or 4895726 or 4925672 or 4939248 or 4166907 or 20010028895 or 20020006919).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
SM	P01	3716583	1973-02-13		Nakamura		

Sarby 4- 1/22/04

84	P02	3781328	1973-12-25		Witte
	P03	3948973	1976-04-06		Phillips
	P04	4072705	1978-02-07		Mieville
	P05	4075000	1978-02-21		Abdulla
	P06	4144232	1979-03-13		Koppel
	P07	4178695	1979-12-18		Erbeia
	P08	4179515	1979-12-18		Mieville
	P09	4235896	1980-11-25		Mieville
	P10	4250191	1981-02-10		Edwards
	P11	4260743	1981-04-07		Bose
	P12	4304718	1981-12-08		Kamiya
	P13	4375475	1983-03-01		Willard
	P14	4443372	1984-04-17		Luo
	P15	4444784	1984-04-24		Hoffman
	P16	4472309	1984-09-18		Kamiya
	P17	4479900	1984-10-30		Luo
	P18	4500456	1985-02-19		Spitzer
	P19	4534786	1985-08-13		Luo
	P20	4564609	1986-01-14		Tamura
	P21	4576748	1986-03-18		Greenlee
	P22	4576749	1986-03-18		Zahler
	P23	4576753	1986-03-18		Kamiya
	P24	4581170	1986-04-08		Mueller
	P25	4595532	1986-06-17		Miller
	P26	4602003	1986-07-22		Malinow
	P27	4602005	1986-07-22		Malinow
	P28	4614614	1986-09-30		Ernest
	P29	4616047	1986-10-07		Lafon
84	P30	4620867	1986-11-04		Luo

84	P31	4633017	1986-12-30		Mueller
	P32	4642903	1987-02-17		Davies
	P33	4675399	1987-06-23		Miller
	P34	4680391	1987-07-14		Firestone
	P35	4739101	1988-04-19		Bourgogne
	P36	4778883	1988-10-18		Yoshioka
	P37	4784734	1988-11-15		Torii
	P38	4794108	1988-12-27		Kishimoto
	P39	4800079	1989-01-24		Boyer
	P40	4803266	1989-02-07		Kawashima
	P41	4834846	1989-05-30		Abramson
	P42	4814354	1989-03-21		Ghebre-Sellassie
	P43	4834846	1989-05-30		Abramson
	P44	4871752	1989-10-03		Zermatter
	P45	4876365	1989-10-24		Kirkup
	P46	4879301	1989-11-07		Umio
	P47	4895726	1990-01-23		Curtet
	P48	4925672	1990-05-15		Gremm
	P49	4939248	1990-07-03		Yoshioka
84	P50	4166907	1979-09-04		Krapcho

Published Applications

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
84	U01	20010028895	2002-10-11		Bisgaier		
			2002-01-				

Sankey 1/22/04

U02	20020006919	17	Thosar
-----	-------------	----	--------

Signature

Examiner Name	Date
<i>Parkypt</i>	<i>1/22/04</i>

Electronic Information Disclosure Statement



RECEIVED
AUG 16 2002
TECH CENTER 1600/2900

COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS

Application:



10/056680

Confirmation: 9993

Applicant(s): Teddy Kosoglou

Docket

CV01492K

Number:

Group Art

1743

Unit:

Examiner:

RECEIVED
AUG 26 2002
TC 1700

(4952689 or 4961890 or 4983597 or 4990535 or 5030628 or 5073374 or 5091525 or 5099034 or 5100675 or 5112616 or 5120729 or 5130333 or 5145684 or 5157025 or 5162117 or 5178878 or 5188825 or 5190970 or 5204461 or 5219574 or 5223264 or 5229362 or 5229381 or 5229510 or 5260305 or 5286631 or 5298497 or 5306817 or 5318767 or 5348953 or 5350868 or 5384124 or 5399363 or 5401513 or 5412092 or 5429824 or 5446464 or 5461039 or 5464632 or 5494683 or 5503846 or 5510118 or 5510466 or 5518187 or 5518738 or 5545628 or 5550229 or 5552160 or 5561227 or 5563264).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
SA	P01	4952689	1990-08-28		Kawashima		

Parky H - 1/22/04

P31	5350868	1994-09-27		Yoshida
P32	5384124	1995-01-24		Courteille
P33	5399363	1995-03-21		Liversidge
P34	5401513	1995-03-28		Wehling
P35	5412092	1995-05-02		Rey
P36	5429824	1995-07-04		June
P37	5446464	1995-08-29		Feldle
P38	5461039	1995-10-24		Tschollar
P39	5464632	1995-11-07		Cousin
P40	5494683	1996-02-27		Liversidge
P41	5503846	1996-04-02		Wehling
P42	5510118	1996-04-23		Bosch
P43	5510466	1996-04-23		Krieger
P44	5518187	1996-05-21		Bruno
P45	5518738	1996-05-21		Eickhoff
P46	5545628	1996-08-13		Deboeck
P47	5550229	1996-08-27		Iwasaki
P48	5552160	1996-09-03		Liversidge
P49	5561227	1996-10-01		Thiruvengadam
P50	5563264	1996-10-08		Kume

Signature

Examiner Name	Date
<i>Pakp...</i>	1/22/04